Chémobiologie
Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 12, Décembre 2014
Chémobiologie
Page(s) 1161 - 1168
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143012020
Publié en ligne 24 décembre 2014
  1. Goffeau A, Barrell BG, Bussey H, et al. Life with 6000 genes. Science 1996 ; 274 : 546 : 63–67.
  2. Schatz G, Haslbrunner E, Tuppy H. Deoxyribonucleic acid associated with yeast mitochondria. Biochem Biophys Res Commun 1964 ; 15 : 127–132. [CrossRef] [PubMed]
  3. Dorée M. Prix Nobel de médecine de Médecine 2001 : Leland H. Hartwell, R. Timothy Hunt, Paul M. Nurse. Le cycle cellulaire couronné. Med Sci (Paris) 2001 ; 17 : 1055–1058.
  4. Galli T, Kuster A, Tareste D. Prix Nobel de Médecine 2013 James Rothman, Randy Schekman et Thomas Südhof. Une récompense pour la découverte des acteurs et des mécanismes moléculaires fondamentaux du trafic vésiculaire intracellulaire. Med Sci (Paris) 2013 ; 29 : 1055–1058. [CrossRef] [EDP Sciences] [PubMed]
  5. Bassett DE, Jr., Boguski MS, Hieter P. Yeast genes and human disease. Nature 1996 ; 379 : 589–590. [CrossRef] [PubMed]
  6. Ishioka C, Frebourg T, Yan YX, et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993 ; 5 : 124–129. [CrossRef] [PubMed]
  7. Szczebara FM, Chandelier C, Villeret C, et al. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Nat Biotechnol 2003 ; 21 : 143–149. [CrossRef] [PubMed]
  8. Perocchi F, Mancera E, Steinmetz LM. Systematic screens for human disease genes, from yeast to human and back. Mol Biosyst 2008 ; 4 : 18–29. [CrossRef] [PubMed]
  9. Guiffant D, Tribouillard D, Gug F, et al. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnol J 2007 ; 2 : 68–75. [CrossRef] [PubMed]
  10. St Onge R, Schlecht U, Scharfe C, Evangelista M. Forward chemical genetics in yeast for discovery of chemical probes targeting metabolism. Molecules 2012 ; 17 : 13098–13115. [CrossRef] [PubMed]
  11. Lenaers G, Amati-Bonneau P, Delettre C, et al. De la levure aux maladies neurodégénératives. Dix ans d’exploration des pathologies de la dynamique mitochondrial. Med Sci (Paris) 2010 ; 26 : 836–841. [CrossRef] [EDP Sciences] [PubMed]
  12. Bonnefoy N, Fox TD. Genetic transformation of Saccharomyces cerevisiae mitochondria. Methods Cell Biol 2001 ; 65 : 381–396. [CrossRef] [PubMed]
  13. Couplan E, Aiyar RS, Kucharczyk R, et al. A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc Natl Acad Sci USA 2011 ; 108 : 11989–11994. [CrossRef]
  14. Aiyar RS, Bohnert M, Duvezin-Caubet S, et al. Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. Nat Commun 2014 ; in press.
  15. Bach S, Talarek N, Andrieu T, et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003 ; 21 : 1075–1081. [CrossRef] [PubMed]
  16. Bach S, Tribouillard D, Talarek N, et al. A yeast-based assay to isolate drugs active against mammalian prions. Methods 2006 ; 39 : 72–77. [CrossRef] [PubMed]
  17. Dormont D. Prix Nobel de Médecine : Stanley B. Prusiner - Un agent infectieux protéique ? Med Sci (Paris) 1997 ; 13 : 1375–1377. [CrossRef]
  18. Liautard JP, Alvarez-Martinez MT, Féraudet C, Torrent J. La protéine prion : structure, dynamique et conversion in vitro. Med Sci (Paris) 2002 ; 18 : 62–69. [CrossRef] [EDP Sciences]
  19. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. Cell 1998 ; 93 : 337–348. [CrossRef]
  20. Wickner RB. [URE3] as an altered URE2 protein : evidence for a prion analog in Saccharomyces cerevisiae. Science 1994 ; 264 : 566–569. [CrossRef] [PubMed]
  21. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998 ; 95 : 13363–13383. [CrossRef]
  22. Nguyen P, Oumata N, Soubigou F, et al. Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. Eur J Med Chem 2014 ; 82 : 363–371. [CrossRef] [PubMed]
  23. Nguyen PH, Hammoud H, Halliez S, et al. Structure-activity relationship study around guanabenz Identifies two derivatives retaining antiprion activity but having lost alpha2-adrenergic receptor agonistic activity. ACS Chem Neurosci 2014.
  24. Oumata N, Nguyen PH, Beringue V, et al. The toll-like receptor agonist imiquimod is active against prions. PLoS One 2013 ; 8 : e72112. [CrossRef] [PubMed]
  25. Tribouillard D, Bach S, Gug F, et al. Using budding yeast to screen for anti-prion drugs. Biotechnol J 2006 ; 1 : 58–67. [CrossRef] [PubMed]
  26. Tribouillard-Tanvier D, Beringue V, Desban N, et al. Antihypertensive drug guanabenz is active in vivo against both yeast, mammalian prions. PLoS One 2008 ; 3 : e1981. [CrossRef] [PubMed]
  27. Pang Y, Kurella S, Voisset C, et al. The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition. J Biol Chem 2013 ; 288 : 19081–19089. [CrossRef] [PubMed]
  28. Tribouillard-Tanvier D, Dos Reis S, Gug F, et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One 2008 ; 3 : e2174. [CrossRef] [PubMed]
  29. Voisset C, Thuret JY, Tribouillard-Tanvier D, Saupe SJ, Blondel M. Tools for the study of ribosome-borne protein folding activity. Biotechnol J 2008 ; 3 : 1033–1040. [CrossRef] [PubMed]
  30. Epstein MA, Barr YM, Achong BG. A second virus-carrying tissue culture strain (Eb2) of lymphoblasts from Burkitt’s lymphoma. Pathol Biol (Paris) 1964 ; 12 : 1233–1234. [PubMed]
  31. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus : 50 years of Burkitt’s lymphoma. Nat Rev Microbiol 2008 ; 6 : 913–924. [CrossRef] [PubMed]
  32. Young LS, Rickinson AB. Epstein-Barr virus : 40 years on. Nat Rev Cancer 2004 ; 4 : 757–768. [CrossRef] [PubMed]
  33. Blake N. Immune evasion by gammaherpesvirus genome maintenance proteins. J Gen Virol 2010 ; 91 : 829–846. [CrossRef] [PubMed]
  34. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003 ; 301 : 1371–1374. [CrossRef] [PubMed]
  35. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995 ; 375 : 685–688. [CrossRef] [PubMed]
  36. Daskalogianni C, Pyndiah S, Apcher S, et al. Epstein-Barr virus-encoded EBNA1 and ZEBRA : targets for therapeutic strategies against EBV-carrying cancers. J Pathol 2014 Sept. 4. doi : 10.1002/path.4431
  37. Voisset C, Daskalogianni C, Contesse MA, et al. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus. Dis Model Mech 2014 ; 7: 435–444. [CrossRef] [PubMed]
  38. Voisset C, Garcia-Rodriguez N, Birkmire A, Blondel M, Wellinger RE. Using yeast to model calcium-related diseases : example of the Hailey-Hailey disease. Biochim Biophys Acta 2014 ; 1843 : 2315–2321. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.